What is aTyr Pharma?
aTyr Pharma is a clinical-stage biotherapeutics enterprise dedicated to the discovery and development of innovative medicines targeting extracellular signaling pathways. The company's research is centered on the biology of tRNA synthetases, a previously untapped area of therapeutic potential. By leveraging a robust global intellectual property portfolio, aTyr is currently prioritizing the development of efzofitimod. This lead product candidate is designed to bind to the neuropilin-2 receptor, effectively downregulating immune engagement in patients suffering from inflammatory lung diseases. Through this specialized focus, aTyr Pharma occupies a distinct niche in the biotechnology sector, bridging the gap between fundamental molecular discovery and high-impact clinical applications.
How much funding has aTyr Pharma raised?
aTyr Pharma has raised a total of $340.3M across 9 funding rounds:
Series B
$10.5M
Series C
$23M
Debt
$10M
Series D
$49M
Series E
$76M
Stock Offering
$86M
Debt
$20M
Share Placement
$45.8M
Share Placement
$20M
Series B (2007): $10.5M with participation from Alta Partners, Cardinal Partners, Polaris Partners, and Imagene
Series C (2010): $23M led by Polaris Ventures, Cardinal Partners, Alta Partners, and Domain Associates
Debt (2013): $10M supported by Silicon Valley Bank
Series D (2013): $49M featuring Cardinal Partners, Alta Partners, Domain Associates, and Polaris Partners
Series E (2015): $76M backed by T. Rowe Price Associates, Rock Springs Capital Management, Deerfield Management, Sofinnova Ventures, Cardinal Partners, EcoR1 Capital, Federated Investors, Alta Partners, Domain Associates, Polaris Partners, and Sphera Global Healthcare
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Debt (2016): $20M led by Solar Capital and Silicon Valley Bank
Share Placement (2017): $45.8M supported by Viking Global Investors, EcoR1 Capital, and Redmile Group
Share Placement (2020): $20M featuring Aspire Capital Fund
Key Investors in aTyr Pharma
T. Rowe Price Associates
T. Rowe Price is a global asset management organization providing investment solutions and financial services to institutions and individuals, with a focus on active management and long-term fundamental research.
Sofinnova Ventures
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in hands-on company building across the entire value chain of healthcare and sustainability investments.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through flexible funding models, data-driven market research, and a commitment to fostering innovation in the biotech ecosystem.
What's next for aTyr Pharma?
With the support of its recent capital injection, aTyr Pharma is well-positioned to accelerate the clinical evaluation of efzofitimod. The company's strategic roadmap focuses on validating its therapeutic platform through rigorous clinical trials while maintaining its intellectual property advantage. As the firm moves deeper into the clinical-stage lifecycle, the focus will likely shift toward optimizing regulatory pathways and exploring potential commercialization partnerships. The continued backing from specialized life sciences investors suggests a strong market appetite for the company's novel approach to treating complex inflammatory conditions, providing the necessary runway to achieve critical milestones in its drug development program.
See full aTyr Pharma company page
